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ABSTRACT 
 
Monita R. Patel: A Study of CD4-Stratified Timing of Antiretroviral Therapy among Patients 
Receiving Integrated Tuberculosis and HIV Treatment in a Highly Resource-Limited Setting 
(Under the direction of Annelies Van Rie) 
 
 
In 2012, the World Health Organization recommended that HIV-infected patients starting 
tuberculosis (TB) treatment be initiated on antiretroviral therapy (ART) after 8 weeks if CD4 
count ≥50 cells/mm3 and after 2 weeks if CD4 count <50 cells/mm3. Examination of this type of 
CD4-stratified ART timing strategy would be useful to inform development and implementation 
of this new recommendation. In the Integration of TB and AntiRetroviral Treatment study, 
nurses implemented a CD4-stratified timing strategy for ART initiation among HIV-infected 
patients starting TB treatment in Kinshasa, Democratic Republic of Congo. Participants were 
eligible for ART initiation at 1 month if CD4 count <100 cells/mm3 or WHO clinical stage 4 for 
reason other than extrapulmonary TB, at 2 months if CD4 count 100-350 cells/mm3, or at 
completion of TB treatment if subsequently CD4 count ≤350 cells/mm3 or WHO clinical stage 4. 
We compared expected and observed timing of ART initiation and used logistic regression with 
backward stepwise elimination to determine predictors of delayed ART initiation, defined as 
deviation from strategy. Subsequently, we used the parametric g-formula to estimate the 
difference in 6-month mortality risk in the population with observed fidelity to CD4-stratified 
ART timing and in the population complete (100%) fidelity to CD4-stratifeid ART timing. Of 
492 adult participants, 235 (47.8%) experienced delayed ART initiation. Contraindication to any 
ARV drug (adjOR 2.91, 95% CI 1.22-6.95), lower baseline CD4 count (adjOR 1.20, 95% CI 
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1.08-1.33 per 100 cells/mm3), TB drug intolerance (adjOR 1.93, 95% CI 1.23-3.02), and non-
disclosure of HIV-infection (adjOR 1.50, 95% CI 1.03-2.18) predicted delayed ART initiation. 
In the subset of 395 patients eligible at 1 or 2 months, mortality risk was 12.0% with observed 
fidelity and 7.8% with complete fidelity, corresponding to a risk difference of -4.2% (95% CI: -
8.1, -0.3, %) and preventable fraction of mortality of 35.1% (95% CI: 2.9-67.9%). 
Timing of ART initiation per CD4-stratified strategy in all patients may be a challenge to 
achieve in highly-resource settings; however, would be worthwhile to further reduce mortality 
among HIV-infected patients with TB. Pragmatic approaches to ensure timely ART initiation in 
those identified at-risk of delayed ART initiation are needed.
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CHAPTER ONE: SPECIFIC AIMS 
Tuberculosis (TB) is among the top fifteen causes of death in the world and is curable 
through a 6-9 month course of anti-tuberculosis treatment.[1]  In 2012, there were approximately 
8.6 million new cases of TB and 1.3 million deaths from TB; the majority of which were in 
limited-resource countries.[2]  Human immunodeficiency virus/acquired immunodeficiency 
syndrome (HIV/AIDS) ranks as the sixth leading cause of death in the world and is manageable 
through life-long antiretroviral therapy (ART).[1]  By end 2012, there were approximately 35 
million people infected with HIV, 2.3 million of which were infected within the preceding year; 
and, 1.6 million deaths from AIDS.[3]  Similar to TB, the majority of AIDS cases and deaths are 
in limited-resource countries.  In fact, a large proportion of patients with TB disease are also 
HIV-infected; TB and HIV/AIDS are overlapping epidemics.  In most countries, the HIV 
prevalence among patients with TB disease is typically higher than that in the general 
population; and in some sub-Saharan countries, as high as 50-80%.[4]  A review conducted by 
Mukadi et al in 2001, found that without ART, case-fatality rates in HIV-infected TB patients 
across several sub-Saharan African countries range from 16-35%.[5]  Thereafter, several 
observational studies have compared mortality between patients with and without ART.  Lawn et 
al reviewed the findings from these studies in 2009 and found that ART reduced mortality in 
HIV-infected TB patients by 54% to 95%.[6]   
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Despite this evidence, the proportion of HIV-infected patients diagnosed with TB who 
initiated ART during TB treatment has only increased from 36% in 2005 to 57% worldwide in 
2012.[2]  One obstacle to ART initiation among HIV-infected TB patients is the need to refer 
patients from the TB clinic to the HIV clinic.  TB treatment services are highly decentralized in 
most countries, while HIV treatment services are not.  Implementation studies have demonstrated 
that the more integrated HIV services are into TB clinical settings, the higher the uptake among 
TB patients.[7, 8]  A second obstacle to ART initiation is the concern among healthcare providers 
that co-treatment for TB and HIV may result in drug-drug interactions, immune reconstitution 
inflammatory syndrome (IRIS), and poor adherence due to high pill burden.  These concerns 
may contribute to delay or failure to initiate ART during the course of TB treatment.   
The World Health Organization (WHO) 2004 “Interim Policy on Collaborative TB/HIV 
Activities” recommended that ART be offered to all TB patients who are eligible per national 
guidelines, but provided no details on timing of ART treatment in patients receiving TB 
treatment. In 2006, the WHO recommended that ART be initiated between 2 weeks and 2 
months after the start of  TB treatment for patients with cluster of differentiation 4 (CD4) count 
<200 cells/mm3, after 2 months for patients with CD4 count 200-350 cells/mm3, or, after 
completion of TB treatment for patients with CD4 count >350 cells/mm3.  This recommendation 
weighs healthcare provider concerns with the level of patient immunosuppression, and provides 
more concrete criteria on when to initiate ART during TB treatment.  No formal evaluation of 
this recommendation was done to date.  Consequently, it is not clear whether this type of CD4-
stratified ART initiation is efficacious or effective.   
In 2009, WHO recommended that ART be initiated in all TB patients within 8 weeks of 
TB treatment, regardless of CD4 count. This recommendation was based on only moderate 
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evidence, and caters to settings in which CD4 cell count is not readily available. Several 
randomized controlled trials (RCTs) evaluated “early” vs. “delayed” ART initiation in TB 
patients.  Results suggest a benefit to “early” ART initiation (within 2-4 weeks), but only among 
those with low CD4 cell count.  The Starting Antiretroviral Therapy at Three Points in 
Tuberculosis (SAPiT) study in South Africa, concluded that starting ART during TB treatment, 
compared to waiting to start ART after completion of TB treatment, reduced the risk of death by 
60%.  Analysis of the two “early” ART arms in SAPiT demonstrated that initiating ART within 
4 weeks v. 2-3 months of TB treatment, relatively reduced the risk of AIDS or death by 70% 
among those with CD4 cell count <50. The Immediate Versus Deferred Start of Anti-HIV 
Therapy in HIV-Infected Adults Being Treated for Tuberculosis (STRIDE) study, conducted 
across multiple countries, demonstrated that initiating ART within 2 weeks v. 2-3 months of TB 
treatment, absolutely reduced the risk of AIDS or death by 11%, only among those with CD4 cell 
count <50.  The Cambodian Early versus Late Introduction of Antiretroviral Drugs (CAMELIA) 
study found that, in a population where 71% of participants have a CD4 cell count < 50 
cells/mm3, the risk of death was relatively reduced by 40% by initiating ART at 2 weeks v. 2 
months of TB treatment.  Taken together, these RCTs suggest that early ART initiation is 
efficacious among those with severe immunosuppression.  For that reason, a CD4-based ART 
timing strategy, such as the one suggested in the 2006 WHO recommendation, may be 
appropriate.  In fact, the recent 2012 WHO TB/HIV Policy for Collaborative TB/HIV Activities 
moves in this direction by recommending that patients with CD4<50 initiate ART within 2 
weeks; and that patients with CD4 ≥50 initiate ART within 8 weeks. 
The proposed analysis will formally evaluate a CD4-stratified ART timing using data 
from the Integration of Tuberculosis and Anti-Retroviral Treatment (ITART) study, conducted 
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by the University of North Carolina (UNC) in the Democratic Republic of Congo.  The main 
objective of this study was to evaluate the feasibility and effectiveness of integrated treatment for 
TB and HIV delivered by nurses at the primary health center-level using a CD4-stratified timing 
strategy based 2006 WHO recommendation. The ITART study generated an electronic database 
that contains data on TB and HIV diagnosis and treatment outcomes, as well as a number of 
covariates of interest for a cohort of adult and children newly diagnosed with TB across 5 sites.  
Data were prospectively collected on patients at baseline/enrollment, monthly follow-up visits 
during TB treatment, and at 6 months post-TB treatment start. 
This analysis will address two specific aims: 
Aim 1: To identify demographic, clinical, and behavioral factors that predict “delayed ART 
initiation” among patients in a highly resource-limited setting; with delayed ART initiation 
defined as ART timing deviating from the CD4-stratified timing strategy.   
Aim 2: To determine the impact of implementation fidelity to ART initiation per CD4-
stratified strategy on mortality, in a highly resource-limited setting.
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CHAPTER TWO: BACKGROUND AND SIGNIFICANCE 
The Burden of TB 
Tuberculosis (TB) is among the top fifteen causes of death in the world and is a major 
source of morbidity and mortality in limited-resource.[1] Tuberculosis (TB) disease is caused by 
infection of Mycobacterium tuberculosis (M.TB).  A subset of those persons with M.TB 
infection will progress to TB disease, a state during which patients are symptomatic and 
infectious.  TB disease is curable through a multi-drug treatment regimen that is typically given 
over the course of six months with close monitoring by health care providers.  Despite this, in 
2012, there were approximately 8.6 million new cases of TB and 1.3 million deaths from TB; the 
majority of which were in limited-resource countries.[1]   
 
The Burden of HIV 
HIV/AIDS ranks as the sixth leading cause of death in the world and is a major source of 
morbidity and mortality in limited-resource settings.[9]  HIV is a virus that transmitted through a 
number of mechanisms, the most common of which globally, is unprotected sex.  HIV infects the 
cells of the immune system.  Persons with HIV-infection progress to AIDS, a disease state 
defined by one or more illnesses indicative of severe immunosuppression.  By end 2012, there 
were approximately 35 million people infected with HIV, 2.3 million of which were 
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infected within the preceding year; and, 1.6 million deaths from AIDS.[3]  Similar to TB, the 
majority of AIDS cases and deaths are in limited-resource countries. 
 
The Burden of TB/HIV 
HIV-infected persons are 20-30 times more likely to develop TB disease after M.TB 
infection and one-fourth of all HIV deaths are attributable to TB disease.[4]  The HIV prevalence 
among patients with TB disease is typically higher than that in the general population; and as 
depicted in Figure 2.1, in some sub-Saharan countries, as high as 50-80%.  In addition, higher 
levels of immunosuppresion are associated with extrapulmonary TB, disseminated TB, and rare 
atypical clinical presentations.  The diagnosis of these types of TB disease is relatively complex 
and may result in treatment delay and subsequently, in increased morbidity and mortality.[10]  
Furthermore, laboratory research suggests that TB disease enhances HIV replication.[11, 12]  This is 
supported by the finding of shorter survival among HIV-infected patients with TB disease 
compared with HIV-infected patients without TB disease in numerous observational cohorts.[13, 
14]
   
 
Mortality Due to TB/HIV in Patients With and Without ART 
A review conducted by Mukadi et al in 2001, found that during the pre-ART era, case-
fatality rates in HIV-infected TB patients across several sub-Saharan African countries ranged 
from 16-35%.[5]  Thereafter, a number of observational studies have compared mortality between 
patients with and without ART and found that ART reduced mortality in patients with TB 
disease by 54% to 95%.[6] 
7 
 
Two of these studies, conducted by Dheda et al in the United Kingdom from 1998 to 
2001 and Haar et al in The Netherlands from 1993-2001, were similar.  The investigators 
retrospectively reviewed medical records to identify HIV-infected patients who were diagnosed 
and treated for TB disease.  The primary objective of these studies was to compare risk of death 
between patients who were treated for TB before and during the ART era.  Dheda et al found a 
72% reduction in mortality (adjusted-HR=0.28; 95% CI: 0.13, 0.63).[15]  Similarly, Haar et al 
found a 54% reduction in mortality (adjusted-OR=0.46; 95% CI: 0.24, 0.89).[16]   
Three of these studies, conducted by Manosuthi et al in Thailand from 2000 to 2004, 
Nahid et al in the United States from 1990 to 2001, and Velasco et al in Spain from 1996 to 
2004, were similar.  The investigators retrospectively reviewed medical records to identify HIV-
infected patients diagnosed and treated for TB disease.  The primary objective of these studies 
was to compare patients the risk of death between patients on and not on ART.  Manosuthi et al 
found that patients not on ART had an increased risk of mortality (adjusted-HR=20.0; 95% CI: 
8.62, 45.45).[17]  Nahid et al found that patients on ART had a decreased risk of mortality 
(adjusted-RR=0.36; 95% CI: 0.14, 0.91).[18]  Velasco et al found that patients on ART had a 
decreased risk of mortality (adjusted-HR=0.38; 95% CI: 0.20, 0.72). 
Although these five studies provide evidence that ART reduces mortality among patients 
with TB disease, they are limited by retrospective study design, and subsequent potential for 
selection, information, and confounding biases, and reverse causality.   
Studies conducted by Akkslip et al in Thailand from 2003 to 2004 and Varma et al in 
Thailand from 2005 to 2006 address this methodological limitation by using a prospective study 
design.  Both of these studies prospectively collected data on HIV-infected TB patients to 
estimate the effect of ART on survival.  Akkslip et al found that ART during TB treatment 
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reduced risk of mortality (adjusted-RR=0.20; 95% CI: 0.1, 0.4).[19]  Varma et al found that ART 
during TB treatment reduced the risk of mortality (adjusted-RR=0.16; 95% CI: 0.07, 0.36).[20]  
These findings confirm the substantial effect of ART on survival among patients with TB 
disease. 
 
Current Uptake of ART Among Patients with TB/HIV 
Despite this evidence, the proportion of HIV-infected TB patients who initiated ART has 
only increased from 36% in 2005 to 57% in 2012.[2]  One obstacle to ART initiation among HIV-
infected TB patients is the need to refer patients from the TB clinic to the HIV clinic.  TB 
treatment services are highly decentralized in most countries, while HIV treatment services are 
not.  Implementation demonstrated that the more integrated HIV services are into TB clinical 
settings, the higher the uptake among TB patients.[7, 8]  A second obstacle to ART initiation is the 
concern among healthcare providers that co-treatment for TB and HIV may result in drug-drug  
interactions, immune reconstitution inflammatory syndrome (IRIS), and poor adherence.  These 
concerns may contribute to delay or failure to initiate ART during the course of TB treatment. 
 
WHO Guidelines on Timing of ART Among Patients with TB/HIV 
The WHO (WHO) 2004 “Interim Policy on Collaborative TB/HIV Activities” 
recommends that ART be offered to all TB patients who are eligible per national guidelines.  
This recommendation was vague and did not address health provider concerns around co-
treatment.  In 2006, WHO recommended that ART be initiated between 2 weeks and 2 months 
for patients with CD4<200, after 2 months for patients with CD4 200-350, or, after completion 
of TB treatment for patients with CD4>350.  This recommendation weighs healthcare provider 
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concerns with the level of patient immunosuppression, and provides more concrete criteria on 
when to initiate ART during TB treatment.  No formal evaluation of this recommendation was 
done to date. Consequently, the effectiveness of this this type of CD4-stratified strategy for 
timing of ART initiation is unclear.   
In 2009, WHO recommended that ART be initiated in all TB patients within 2-8 weeks, 
regardless of CD4 count.  This recommendation was based on only moderate evidence, and 
caters to settings in which CD4 count is not readily available.  Based on the results of 3 recent 
RCT studies, 2012 WHO TB/HIV Policy for Collaborative TB/HIV Activities recommended that 
patients with CD4<50 initiate ART within 2 weeks; however, still suggest that all other patients 
be initiated within 8 weeks regardless of CD4 count. This reflects a shift back toward CD4-
stratified timing of ART initiation. 
 
Predictors of Delay of ART Initiation in TB Clinical Settings 
Lawn et al conducted a retrospective observational study among HIV-TB patients from 
one site in South Africa from 2002 to 2008.  The purpose of this study was to quantify and 
explore determinants of time delay between TB treatment start and ART initiation.  Patients were 
categorized by whether they received integrated TB/HIV care, defined as diagnosis and 
treatment of TB within the HIV clinic; or non-integrated TB/HIV care, defined as diagnosis and 
treatment of TB within the TB clinic and referral to HIV clinic for ART.  Competing risk 
regression and time to event analyses were used to account for the possibility of death or loss-to-
follow-up before ART initiation.  The proportion of patients who initiated ART during TB 
treatment was similar (86% and 89%) across patients who did and did not receive integrated 
TB/HIV care.  However, the median time to ART initiation was lower among patients who were 
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receiving integrated TB/HIV care, than among those who were not (41 days versus 116 days; p-
value <0.0001).[21]  The proportion of patients who initiated ART within 8 and 12 weeks was 
significantly lower among patients receiving non-integrated TB/HIV care (19% and 24%, versus, 
59% and 77%; p<0.001).  Recent calendar period, lower CD4 cell count, smear-positivity, 
extrapulmonary TB, and integrated TB/HIV care, were each independently statistically 
associated with shorter time to ART initiation; while, age, gender, and new/recurring TB status, 
were not.  Although successful in quantifying the time to ART initiation, especially between 
patients who did and did not receive integrated TB/HIV care; this study falls short in identifying 
predictors of time to ART initiation.  The number and scope of predictor variables assessed, 
especially those that would be potentially modifiable, were limited; and there is a need for more 
comprehensive study. 
Lawn et al conducted a similar second study in South Africa from 2002 to 2008 with the 
same primary objective.  This study included patients from across three non-integrated TB/HIV 
care sites and used accelerated failure time modeling.  In this study, the mean time to ART 
initiation was 2.66 months (IQR: 1.58, 4.17).[22]  Lower CD4 count, more recent calendar year, 
and clinic site, were each independently significantly accelerated time to ART initiation; while, 
age, gender, new/reoccurring TB status, and type of TB were not.  This study has similar 
limitations as the other study by Lawn et al, and additionally, does not account for competing 
risks to ART initiation including death and loss-to-follow-up. 
Chilton et al conducted a retrospective observational study of factors contributing to 
delay in ART initiation, defined as counter to the 2006 WHO recommendations described above, 
among HIV-infected patients with TB disease in an urban site in the United Kingdom from 1998 
to 2007.  Overall, of the 83 patients who should have initiated ART, 63 (76%) had delay in ART 
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initiation.  The reasons for delay varied by patient CD4 category.[23]  The reason for delay in 
patients with CD4<100 seems to be clinically-related and physican-determined; while in patients 
with CD4>200 seems to be non-clinical and patient-determined.  A major limitation of this study 
was that reason for delay was collected from existing medical records, which limits the ability to 
obtain specific information and also creates potential for information bias.  In addition, this study 
was conducted in the United Kingdom and the reasons for delay may not translate to limited-
resource settings.   
Although these studies provide some insight in to factors that may predict timely ART 
initiation, they are few and all have limitations that justify Aim1 of the proposed study. 
 
Timing ART Initiation in HIV Patients in General 
There is extensive body of published research that examines the optimal time to initiated 
ART in HIV-infected patients in general.  All of these studies examine the impact of initiating 
ART at different time points corresponding to a patient’s CD4 cell count fall below a specified 
value.  Early randomized controlled trials conducted in severely immuno-compromised patients 
(with CD4<200 cells/mm3) showed that ART initiation can reduce the rate of AIDS or death by 
half.[24, 25]  Based on this evidence, WHO issued guidance in 2004 that recommended ART 
initiation in patients with CD4<200.  The question of whether the benefit of ART would hold in 
HIV-infected patients with higher CD4 counts remained unanswered.  Since then, several 
observational and randomized controlled trials have examined this question. 
There have been four major observational studies conducted among HIV-infected 
patients (both with and without TB) that have aimed to examine whether initiation of ART when 
a patient’s CD4 cell count is <350 cells/mm3 provides clinical benefit.  Investigators from the 
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When to Start Consortium conducted a retrospective observational study of 21,247 HIV-infected 
patients who initiated ART at CD4 cell count <550 cells/mm3 across 15 cohorts in the United 
States and Europe between 1998 and 2006.[26]  The primary finding from this study was that 
initiating ART at CD4 cell count 251-350 cells/mm3, compared to initiating at CD4 cell count 
351-450 cells/mm3, resulted in increased risk of incident AIDS or death (HR=1.28; 95% CI: 
1.40 - 1.57).  Kitahata et al conducted an retrospective observational study that included parallel 
analyses of 8362 patients from 1996 to 2005 with baseline CD4 cell count 351-500 cells/mm3 
and 9155 patients with baseline CD4 cell count >500 cells/mm3.[27]  The primary findings of this 
study were that deferment (v. immediate initiation) of ART was associated with a higher risk of 
death in both groups of patients. In patients with baseline CD4 cell count 351-500 cells/mm3, the 
RR=1.69; 95% CI: 1.26 - 2.26; in patients with baseline CD4 cell count >500 cells/mm3, the 
RR=1.94; 95% CI: 1.37 – 2.79).  Kaplan et al conducted an observational study of 4976 patients 
from 1996 to 2002 who initiated ART across a range of baseline CD4 cell counts.[28]  The 
primary finding from this study was that initiation of ART at lower CD4 cell count was 
associated with an increased hazard of death (HR=6.3, 3.5, 1.7, 1.5; for initiation at CD4 cell 
count of 0-49, 50-199, and 200-349, 350-499, compared to the referent of ≥500 cells/mm3).  
Jonsson Funk et al conducted an observational study of patients in the CASCADE collaboration 
(composed of multiple clinical cohorts in Europe) from 1996 to 2009.[29]  The investigators used 
sequential nested cohorts to examine the effect of starting ART within a given month within 
specified CD4 strata.  The primary finding of this study was that compared with deferring ART 
within a given month, ART initiation at CD4 cell count <500 cells/mm3 was associated with 
lower disease progression (HR range: 0.32-0.75).  Taken together, all of these observational 
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studies suggest that initiating at either <350 or <500 CD4 cell count is warranted in the general 
HIV population. 
Two RCTs have aimed to examine whether initiation of ART when a patient’s CD4 cell 
count is <350 cells/mm3 provides clinical benefit.  In the first of these, the multi-site 
international Strategies for Management of Antiretroviral Therapy (SMART) RCT, investigators 
randomized patients with CD4<350 cells/mm3 to two treatment groups; one in which ART was 
initiated immediately and one in which ART was initiated when CD4 cell count fell to <250 
cells/mm3.[30] The primary finding of this study was that patients who initiated ART at CD4<250 
cells/mm3 (compared to <350 cell/mm3) had higher risk of death or opportunistic infection 
(HR=3.47; 95% CI: 1.26-9.56).  In the second, conducted in Haiti by Severe et al, HIV-infected 
patients with 200<CD4<350 cells/mm3, were randomized to received immediate ART or ART 
delayed until CD4 fell below 200 cells/mm3 and followed up for the primary endpoint of death.  
This study was stopped by the DSMB at interim analysis due to substantially higher mortality in 
the delayed ART group (HR=4.0; 95% CI: 1.6-9.8).[31]   
Based on the evidence from these studies, in 2009 the WHO recommendation 
rais5ty56ed the recommended CD4 cell count threshold for ART initiation from 200 to 350 
cells/mm3. 
 
Timing of ART Initiation in Patients with TB/HIV 
The SAPiT RCT by Abdool Karim et al in South Africa, examined the effect of ART 
initiation after 1 month (early-integrated arm), 2 months (late-integrated arm) , or 6 months 
(sequential arm) of starting TB treatment, on mortality and AIDS.  The study population 
consisted of 642 HIV-infected patients aged 18 or older, with baseline CD4<500, and smear-
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positive, pulmonary TB disease.  Patients were followed-up for a maximum of 2 years.  An 
interim analysis was conducted approximately three months after the end of study recruitment.  
The main finding of this analysis was that ART initiation under either of the integrated arms, 
reduced mortality by 54% (HR=0.44; 95% CI: 0.25-0.79).[32]  Based on the results of this 
analysis, the data safety and monitoring board (DSMB) required that all patients in the sequential 
arm who had not initiated ART, be offered ART as soon as possible.  The subsequent analysis 
compared the early-integrated and late-integrated  arms, with stratification across baseline CD4 
categories.  The main finding from this analysis was that ART in the early integrated arm 
reduced the risk of mortality or AIDS, however, only among patients with baseline CD4<50 
(stratum-specific HR=0.32; 95%: 0.07-1.13).[33]  Patients in the early integrated arm had a higher 
incidence of IRIS and this effect was inversely proportional to baseline CD4 [among CD4>50, 
IRR=2.16 (1.12, 4.47); among CD4<50, IRR=4.71 (1.48, 19.64)].  The findings of the study did 
not suggest that earlier ART had any effect on adherence or outcome of TB treatment.  A major 
limitation of this study is that was not originally powered for stratified analysis using the CD4 50 
cut-point.  There were only 35 patients with CD4<50, and this may have contributed to the lack 
of statistical significance for several of the key outcomes. 
The STRIDE RCT by Havlir et al in multiple countries, examined the effect of ART 
initiation within 2 weeks (earlier ART) or between 2 and 3 months (later ART), on mortality or 
AIDS.  The study population consisted of 806 HIV-infected patients aged 13 years or older, with 
baseline CD4 cell count<250, and confirmed or probable TB disease based on either smear or 
culture or clinician assessment.  Patients were followed-up for a maximum of 2 years.  The main 
finding of this study was that earlier ART reduced the risk of mortality or new AIDS-defining 
illness, however, only among patients with CD4<50 cells/mm3 (15.5% v. 26.6%; p=0.02).[34]  The 
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risk of IRIS was higher in the earlier ART group, compared to the late ART group, regardless of 
baseline CD4 cell count (11% v. 5%; p<0.001), however; none of the deaths that occurred were 
attributable to IRIS.  In contrast to the SAPiT study, the STRIDE study was powered for 
stratified analysis by baseline CD4 cell count ≥ or <50 and patients.  A major limitation of 
STRIDE, however, was that the results are presented as an absolute risk (not rate or hazard), and 
does not take into account actual person-time at risk.  For example, it is not clear how the 62 
patients who were lost to follow-up or withdrew from the study were analyzed, since they were 
not at risk for the entire 48 week period.  If the person-time at risk varied across the two study 
groups, this may potentially impact the main study finding; however, this is not addressed by the 
investigators. 
The CAMELIA RCT by Blanc et al in Cambodia, examined the effect of ART initiation 
at 2 weeks (earlier ART) or at 8 weeks (later ART), on mortality.  The study population 
consisted of 661 HIV-infected patients aged 18 years or older, with CD4 cell count<200, and 
smear-positive TB disease.  Patients were followed-up for a minimum of 50 of weeks.  The main 
finding of this study was that earlier ART reduced the risk of mortality [HR=0.62; 95% CI: 
(0.44-0.86)].[35]  The risk of IRIS was higher in the earlier ART group, compared to the later 
ART group [HR=2.51; 95% CI: (1.78-3.59)].  There was no difference in adherence to or 
outcome of TB treatment across the two study arms.  A prime difference between CAMELIA 
and the other two RCTs, is that the study population was much more immunosuppressed.  This is 
partly due to the enrollment criteria, which limited the study population to patients with CD4 cell 
count <200, however; even among those patients who met this criteria, the majority (71%) had 
CD4 cell count <50.  Whether this study population is representative of HIV-infected patients 
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with TB disease, especially in other geographic settings such as sub-Saharan Africa, is 
questionable. 
The TIME RCT by Manosuthi et al in Thailand, examined the effect of ART initiation at 
4 weeks or at 12 weeks, on the primary endpoint, mortality at 1-year.  The study population 
consisted of 156 HIV-infected patients aged 18-65 years, with CD4 cell count<350, clinically or 
bacteriologically diagnosed active TB, no previous ART, and normal serum creatinine and 
aspartate aminotransferase and alanine aminotransferase (ALT) levels.  Additionally, pregnant 
women were excluded from the study.  The intended follow-up period was 96 weeks, however, 
because this study was prematurely ended on May 2011, some patients had shorter or insufficient 
follow-up and consequently, power was only 70%.  The primary finding of this study was no 
statistically significant association between early ART initiation and mortality at 1-year 
(RR=0.85; 95% CI: (0.25 – 2.89).[36]  In contrast to previous studies, this finding did not change 
after stratification by CD4 count; in fact, although still non-significant, the direction of the effect 
changed from protective to harmful [RR=1.59; 95% CI: (0.40 – 6.40) among CD4 count <50 
cells/mm3 and RR=1.24; 95% CI: (0.34 – 4.54), among CD4 count <100 cells/mm3].   
A retrospective observational study by Manosuthi et al in Thailand, examined the effect 
of initiating ART at 2, 4, 6, 9 and 12 months (versus not) on mortality.  The study population 
consisted of 411 HIV-infected patients, aged 15 years or older, and, diagnosed and treated for TB 
between January 2000 and December 2004.  The main finding from this study was that ART 
initiation within 6, 9, and 12 months were associated with reduced mortality (HR range: 2.37-
2.68; p<0.05); while, ART initiation within 2 or 4 months, was not.[17]  This finding is consistent 
with integrated v. sequential analysis from the SAPiT trial, but is counter to the early v. late 
analyses within the 6 months of TB treatment from all three RCTs.  There are several potential 
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methodological reasons for this discrepancy.  For example, it is not clear what sample sizes in 
each exposure category were generated by each of the timing cut-points.  Since this study was 
not randomized, if only a small proportion of patients initiated ART within 2 months or 4 
months, this may have negatively affected power to detect a difference using these cut-points.  
Furthermore, it is not clear whether the investigators adjusted for covariates in the models used 
to generate the HR estimates for the timing analyses; a necessary step to address potential 
confounding bias. 
A prospective observational study by Varma et al in Thailand, examined the effect of 
initiating ART within various timepoints following start of TB treatment (versus not) on 
survival.  The study population for timing analyses consisted of 200 HIV-infected patients, aged 
17 or older, receiving treatment for TB disease for <4 weeks between May 2005 and Sep 2006, 
who initiated ART during the period of TB treatment.  The main finding from this study was that 
ART initiation within 4 months (versus not), improved survival among bacteriologically 
confirmed cases of TB disease (HR=9.0; 95% CI: 1.1-73.0).  Overall, there appeared to be a 
linear relationship between time to ART initiation and mortality; the longer ART was delayed, 
the higher the risk of mortality.  Although, a Cox proportional hazards model was used to 
generate these estimates, because of the relatively small sample size, the investigators only 
adjusted for the severity of TB disease and baseline CD4 count.  In addition, the incidence of 
IRIS was not studied according to ART timing status; therefore, the potential trade-off associated 
with early initiation was not apparent.  
A retrospective observational study by Velasco et al in Spain, examined the effect of 
initiating ART within 2 months v. at 3 months or more on mortality.  The study population 
consisted of 313 HIV-infected adults, diagnosed with TB disease between 1996 and 2004, who 
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initiated ART between time of TB diagnosis and the end of the study period.  The main finding 
of this study was that ART initiation within 2 months reduced mortality, particularly in the time 
soon after TB diagnosis [adjusted-HR: for 6 months=0.15 (0.03-0.59); 1 year=0.33 (0.14-0.78); 
full follow-up period=0.37 (0.17-0.66)].[37]  A major limitation of this study is the retrospective 
design and subsequent potential for selection, information, and confounding biases, and reverse 
causality.  In addition, because this study was conducted in Spain, the results may not be 
generalizable to limited-resource settings. 
A retrospective observational study by Franke et al in Rwanda, utilized advanced 
modeling methods to examine the effect ART initiation at various timepoints during TB 
treatment on survival.  The study population consisted of 308 HIV-infected patients, aged 15 
years or older, with baseline CD4 cell count <350, who were treated for TB disease at one of 5 
ART sites between January 2004 and February 2007.  The probability of survival was modeled 
to simulate a hypothetical scenario in which all patients with baseline CD4 cell count of 50, 100, 
200 or 300 cells/mm3, initiate ART at 15, 30 60, 180 days, or not at all, after start of TB 
treatment.  Survival probabilities for ART initiation at 30, 60, 180 days and not at all, were 
statistically lower than for 15 days, but only when baseline CD4 cell count was set to 50 or 100 
cells/mm3.[38]  A major limitation of this study is use of advanced modeling methods that make 
additional assumptions beyond those in typical regression modeling that is used in 
epidemiological studies.  A key assumption is that the model that was used to generate survival 
probabilities was correctly specified and provided accurate predictions.   The reliance on 
retrospective observational data, may contribute to violation of this assumption.  In addition, this 
study population was receiving both TB treatment and ART services at ART clinic; a scenario 
which is not the norm in most sub-Saharan African settings, and may not be representative. 
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As summarized in Table 2.1, taken together, these studies suggest that ART initiation 
early during the course of TB treatment may offer a survival benefit; however, only among 
patients with severe immunosuppression.  For that reason, a CD4-stratified timing strategy for 
ART initiation, such as the one suggested in the 2006 and 2012 WHO recommendations, may be 
appropriate. 
Translation of RCT Findings into Real-World Practice: Implementation Fidelity 
Findings from RCTs are not always replicable in less strictly controlled settings; this is 
particularly likely at the primary care level in resource-limited settings. Observational studies 
from sub-Saharan Africa have found that most patients initiate ART late, after 8 weeks of TB 
treatment.[6-10] Lack of integration of TB and HIV treatment services has been identified as one of 
the key contributors to this delay.[9, 10] Interventions to integrate TB and HIV services have been 
shown to reduce, but not eliminate delay in ART initiation.[11, 12]  
Implementation fidelity, defined as the degree to which an intervention is implemented as 
intended, is a potential modifier of the relationship between an intervention and its intended 
outcome and is an important component of translating evidence-based recommendations into 
clinical practice.[13, 14] Achievement of high implementation fidelity is one of the best ways to 
replicate the success an intervention has achieved in RCT studies.[13] Low fidelity to interventions 
or guidelines can explain differences between outcomes observed in routine clinical settings and 
those achieved in RCT studies. The relatively low coverage of timely ART initiation in patients 
with TB suggests that implementation fidelity to the 2012 WHO guidelines for timing of ART 
initiation in TB patients may be a challenge in routine care settings, even when HIV and TB 
services are integrated. Data on implementation fidelity in resource limited settings and its 
effects on desired outcomes are limited.  
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Figure 2.1 Estimated HIV Prevalence in New Cases of Tuberculosis Disease, 2012 
 
Source: Global Tuberculosis Report 2013, World Health Organization 2013. 
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Table 2.1 Summary of Studies of Effect of ART Timing Among HIV-infected Tuberculosis Patients on Clinical Outcomes of Interest 
Study Country/ Design Study Population 
ART Timing 
Exposure Outcome 
    Death AIDS or death 
SAPiT – 
Abdool 
Karim et 
al, 2010 & 
2011 
S. Africa/ 
RCT 
• HIV+  
• ≥18  
• smear+ PTB  
• CD4<500  
• (N=642) 
Within 2 
months v. after 
6 months (ref) 
HR=0.44  
(0.25, 0.79) 
Not studied. 
Within month 
v. within 2-3 
months (ref) 
Death: NS, but, few events, 
and small sample of patients 
with CD4<50 (N=37) 
Among 
patients with 
CD4<50, 
IRR=0.32 
(0.07, 1.13) 
ACTG 
5221 – 
Havlir et 
al, 2011 
Multiple/ 
RCT 
• HIV-infected 
• ≥13 yrs 
• confirmed or  
probable TB  
• CD4<250 
• (N=806) 
Within 2 
weeks v. 
between 8 and 
12 weeks (ref) 
Not studied as an outcome 
separate. 
Among 
patients with 
CD4<50, 
proportion 
with outcome= 
15.5% v. 
26.6%; (1.5 – 
20.5%; p=0.02 
CAMELIA 
– Blanc et 
al, 2011 
Cambodia/ 
RCT 
• HIV-infected 
• ≥18 yrs 
• smear+ TB 
• CD4≤200 
• (N=661) 
At 2 weeks v. 
at 8 weeks 
(ref) 
HR=0.62 (0.44-0.86) Not studied. 
TIME – 
Manosuthi 
et al, 2012 
Thailand/ 
RCT 
• HIV-infected 
• 18-65 yrs 
• Clinical or bacteriology 
confirmed TB 
• CD4<350 
• (N=156) 
At 4 weeks v. 
at 12 weeks 
(ref) 
RR=0.85 (0.25 - 2.89) Not studied, 
but 
hospitalization 
was: RR=1.14 
(0.59 – 2.22) 
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Manosuthi 
et al, 2006 
Thailand/ 
retrospective 
observational 
• ART-naïve 
• HIV-infected 
•  ≥15 yrs 
• Dx and Tx TB between Jan 
2000 and Dec 2004 
• treated for TB 
• (N=411 on ART) 
Binary using 2 
month cutpoint 
Survival: HR=2.04 (0.69-
6.00) 
Not studied 
Binary using 4 
month cutpoint 
Survival: HR= 1.97 (0.83-
4.72) 
Not studied 
Binary using 6 
month cutpoint 
Survival: HR=2.65 (1.15-
6.10) 
Not studied 
Binary using 9 
month cutpoint 
Survival: HR=2.68 (1.26-
5.68) 
Not studied 
Binary using 
12 month 
cutpoint 
Survival: HR=2.37 (1.11-
5.06) 
Not studied 
Varma et 
al, 2009 
Thailand/ 
Prospective 
observational 
• HIV-infected 
• Receiving TB Tx <4 weeks at 
enrollment between May 2005 
and Sep 2006 
• >17 years 
• (N=200); restricted timing 
analysis to patients who 
initiated ART during TB 
treatment 
Binary using 
various timing 
cutpoints 
Survival: 4 month cutpoint, 
among bacteriologically 
confirmed TB cases, HR=9.0 
(1.1-73.0) 
 
Other cutpoints: NS 
Not studied 
Within 2 
months v. 
at  ≥3 
months 
(ref) 
Spain/ 
Retrospective 
observational 
 
• HIV-infected 
• Adult 
• Dx TB between 1996-2004 
• ART naïve at TB Dx, but on 
ART 
• (N=313) 
 Over full follow-up period: 
HR=0.37 (0.17-0.66) 
At 6 months follow-up:  
HR= 0.15 (0.03-0.59) 
At 1 year  follow-up 
HR=0.33 (0.14-0.78) 
Not studied 
Franke et 
al 
Rwanda/ 
Retrospective 
observational 
and modeling 
• HIV-infected 
• >15 years 
• CD4≤350 
• ART naïve 
• TB Tx Jan 2004  Feb 2007 
• (N=308) 
ART at 15 
(ref), 30, 60 or 
180 days after 
start TB Tx 
Survival probabilities for 30, 
60, 180 days were 
statistically lower than for 15 
days, but only when baseline 
CD4 was set to 50 or 100 
Not studied 
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CHAPTER THREE: STUDY DESIGN AND METHODS 
 
Overview of the ITART Study 
UNC has provided programmatic and technical support to the School of Public Health at the 
University of Kinshasa to implement programmatic and research activities to strengthen and 
expand HIV prevention, care, and treatment services in DRC, since 2001.  These activities 
include scaling up HIV testing and access to ART among patients diagnosed with TB, who have 
a higher HIV prevalence than the general population in DRC.  In 2008, Van Rie et al published 
the results from a preliminary study conducted among 1238 TB patients across three UNC-
supported clinics.[8]  This study aimed to identify the best model for implementation of HIV 
testing among TB patients.  The primary finding from this study was that a provider-initiated 
counseling and testing (PITC) model in which TB nurses offer HIV testing in the TB clinic 
resulted in high uptake of HIV testing (98%) compared to the traditional model of referral to off-
site VCT (69%).  The HIV prevalence among TB patients who accepted HIV testing was 19% 
(N=205), which is consistent with national estimates for DRC.  Of these 205 patients who were 
HIV-infected, only 21 were able to access ART, of whom 9 were already receiving ART before 
they were diagnosed with TB and of who 2 started ART after TB treatment were completed.  
This study provided evidence for integration of HIV services into TB clinical settings and 
rationale for integration of HIV care and treatment services, including provision of ART. 
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Study Design of the ITART Study 
The ITART study was a prospective observational cohort study consisting of patients diagnosed 
with TB disease and identified as HIV-positive as a part of TB diagnosis, who were offered ART 
within the TB clinic under a nurse-driven integrated model.  The study enrolled 599 patients 
from August 2007 to November 2009.  Inclusion criteria for the study were: 1. initiation of 
treatment for TB disease at one of 5 participating health centers, and, 2. confirmation of HIV-
infection, and, 3. willingness and ability to provide informed consent.  Exclusion criteria for the 
study were: 1. treatment for TB at non-participating health center, or, 2.on ART at time of TB 
diagnosis and preference to continue ART at a non-participating health center.  Patients were 
informed of study by the on-site UNC counselor/nurse and asked for written informed consent to 
participate. The study was approved by institutional review boards at both UNC at Chapel Hill 
and the University of Kinshasa.   
At enrollment, all patients were administered a baseline questionnaire that included 
demographic, clinical, and behavioral data deemed relevant to the study aims.  In addition, 
laboratory testing including CD4, alanine aminotransferase (ALT), hemoglobin, and a physical 
exam were conducted.  Patients were assessed for ART initiation at enrollment.  A CD4-
stratified based timing strategy in line with the 2006 WHO recommendation was used by health 
care providers to decide when to initiate ART after TB treatment start.  In this algorithm, patients 
should be initiated on ART at 1 month after TB treatment start, if baseline CD4<100 cells/mm3 
or baseline WHO clinical stage 4 condition other than extrapulmonary TB, or 2 months after TB 
treatment start, if baseline CD4 100-350 cells/mm3. Patients with baseline CD4>350 were 
reassessed at month 5 of TB treatment; ART was initiated if and when CD4 fell below 350 
and/or WHO clinical stage 4 conditions were present.   
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Patients on ART were scheduled to receive CD4 and viral load testing every 6 months 
following ART initiation.  Patients were scheduled for follow-up visits weekly during the first 
two month of TB treatment, monthly from the third month to the end of TB treatment, at the end 
of TB treatment, and semiannually after the end of TB treatment.  During follow-up visits, in 
addition to any scheduled laboratory testing, a physical exam and questionnaire on adherence, 
sexual behavior, and disclosure status were administered.  Patients who were more than 3 days 
late for a scheduled follow-up visit were traced using TB clinic nurses.  If necessary, study staff 
contacted patients by phone or by home visit on 2 attempts before being regarded as “lost-to-
follow-up”.  Other reasons for inactivation from the study including death, loss-to-follow-up, and 
voluntary withdrawal were also documented.  Per study strategy, patients received ART in the 
TB clinic during the period of TB treatment, and then were transferred to the ART clinic on-site 
within the same facility.  In addition, based on patient preference, some patients were 
transferred-out of the study to continue their TB treatment and/or ART at a non-ITART clinic.  
Patients were also administratively censored at the end the ITART study (in February 2010). 
The overall (descriptive) cohort analyses for pediatric and adult patients in ITART have 
already been conducted, and provide valuable preliminary data for this dissertation study. 
 
Analytical Population 
The specific aims were achieved through secondary analysis of the ITART study data.  As 
depicted in Figure 3.1, additional inclusion/exclusion criteria were applied to the larger ITART 
study population.  The analytical population for Aim1 included patients who were: 1. aged ≥13 
years at enrollment, 2. ART naïve at enrollment, 3. enrolled in ITART within 1 month of their 
TB treatment start date, and 4. had baseline CD4 count (within 30 days of and closest to TB 
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diagnosis date, prior to ART initiation) available. The analytical population for Aim2 used the 
analytical population for Aim1 as a starting point and additionally excluded patients who were 
not eligible to initiate ART at 1 month or 2 months based on baseline CD4 and/or WHO staging 
criteria e.g. CD4>350 and no WHO stage 4 condition. Based on this, the analytical population 
for Aim1 included 492 patients, and the analytical population for Aim2 included 395 patients. 
 
Exposure/Outcome Assessment 
For Aim1, there was not a primary exposure since it focused on identifying predictors of the 
main outcome, which is binary: delayed ART initiation (or not).  To define timing of ART 
eligibility, we compared the ART initiation date with TB treatment start date. To accommodate 
scheduling limitations, clinic closure on weekends and holidays, and on-site availability of 
consulting physician, patients eligible for ART initiation at 1 month of TB treatment who were 
expected to, but did not initiate ART within 1 month plus 5 days of TB treatment, were classified 
as experiencing delayed ART initiation. Similarly, a 5 day window was applied to define delayed 
ART initiation among patients eligible for ART initiation at 2 months and completion of TB 
treatment. Patients who died or were LTFU prior to the time they were eligible plus 5 days who 
did not initiate ART, were not categorized as experiencing delayed ART. Patients with both 
baseline and follow-up CD4 count >350 cells/mm3 who did not experience a WHO stage 4 
condition during TB treatment, were also categorized as not experiencing delayed ART, since 
they were not scheduled to initiate ART during TB treatment.  
For Aim 2, the main exposure was binary: ART initiation per CD4-stratifed timing strategy (or 
not).  The main outcome was all-cause mortality at 6-months from the start of TB treatment, the 
duration of first-line TB treatment. Data on if and when a patient died during the follow-up 
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period were systematically collected on the patient inactivation form.  LTFU was defined as in 
the ITART study protocol. Patients who were lost to follow up (LTFU) prior to six months were 
assigned a missing outcome. 
 
Covariate Assessment/Definitions 
 
For Aim1, all covariates hypothesized as potential predictors of delayed ART initiation based on 
subject matter knowledge and previously published literature were assessed. For Aim2, 
covariates were selected for inclusion in a directed acyclic graph (DAG) of the association 
between ART timing per CD4-stratified strategy and mortality at 6-months (Figure 3.4), based 
on published literature and subject matter knowledge. Descriptive statistics, distribution of 
association across sub-categories, substantive area standards, and clinical/programmatic 
relevance will be considered to define and categorize each covariate as detailed in Table 3.1. 
 
Analytical Approach – Aim1 
For Aim1, we used a logistic regression model to identify covariates that are predictive of delay 
in ART initiation (main outcome as defined above) in the analytical population (N=492). This 
model was selected because the predictor variables include a combination of both continuous and 
categorical variables and the outcome variable will be modeled as a categorical, and in this 
instance we are not attempting to estimate “risk”’; rather, we are attempting to estimate the odds 
or “ predicted probability” of experiencing delay in ART initiation. 
We selected demographic, behavioral, and clinical covariates that may be predictive of delayed 
ART initiation based on previously published literature and subject matter knowledge. We first 
ran a full logistic model containing all selected covariates. Subsequently, we used a backwards 
elimination stepwise method to generate a final (reduced) predictive model. Covariates were 
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assessed in order from highest to lowest Wald chi-square and eliminated from the model based 
on the likelihood ratio test using an alpha of 0.05. 
In addition, we stratified patients by expected timing (1 month, 2 months, end of TB treatment, 
or deferred TB treatment) and then categorized observed timing as: 1. initiating ART before or at 
the expected time, 2. initiating ART after the expected time, or 3. not initiating ART. The 
median and interquartile range of delay was calculated with each stratum of patients whose ART 
initiation was after expected. 
 
Analytical Approach – Aim2 
For Aim 2, logistic regression and the parametric g-formula was used to estimate the difference 
in mortality risk under observed and complete implementation fidelity to the strategy for CD4-
stratified timing of ART initiation used in the ITART study. 
We used a logistic regression model to assess baseline covariates, including timing of ART 
initiation, as potential predictors of mortality. We first ran a full logistic model containing all 
selected covariates. Subsequently, we used a backwards elimination stepwise method to generate 
a final (reduced) predictive model. Covariates were assessed in order from highest to lowest 
Wald chi-square and eliminated from the model based on the likelihood ratio test using an alpha 
of 0.10. We estimated crude (OR) and adjusted (adjOR) odds ratios with 95% confidence 
intervals (CI). 
In implementation science, implementation fidelity is defined as the degree to which programs 
are implemented as intended, with a focus on content or frequency of the intervention.[43] In this 
study, we defined implementation fidelity to the CD4-stratified ART initiation strategy as the 
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proportion of individuals who initiated ART timely, i.e. according to a priori defined CD4 
criteria. We calculated each patient’s timing of ART initiation, by comparing the ART start date 
with TB treatment start date. We categorized timing of ART initiation as per CD4-count strategy 
(per strategy) or deviating from CD4-count strategy (not per strategy); similar to how delayed 
ART initiation was defined in Aim 1. To accommodate for scheduling limitations, clinic closure 
on weekends and holidays, and limited availability of consulting physician, a five-day grace 
period was added to the one or two month of TB treatment to define ART initiation per strategy. 
Participants who initiated ART prior to the time they became eligible were classified as per 
strategy. Participants who died or were LTFU prior to eligibility for ART and had not initiated 
ART were categorized as initiating ART per strategy, since not initiating ART prior to death or 
LTFU did not constitute deviation from the CD4-stratified strategy. In sensitivity analyses, we 
explored the impact of narrowing the definition of ART initiation per strategy to exclude patients 
who were LTFU prior to time of ART eligibility, a subset of patients who could have started 
timely ART had they been retained in care. 
Differences in proportions and medians of baseline characteristics between patients initiating 
ART per strategy and those initiating not per strategy were assessed using chi-square or Fisher’s 
exact tests and Kruskal-Wallis tests, respectively.  
In our study observed timing of ART initiation likely deviated from assigned timing of ART 
initiation in a proportion of patients, resulting in incomplete implementation fidelity. To estimate 
the causal effect of implementation fidelity, we need to compare mortality in the study 
population under observed intervention fidelity with mortality in the study population with 
complete implementation fidelity (depicted in Figure 1).[44][45] Due to the observational nature of 
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our study, we did not have a comparison group and were not able to directly observe mortality in 
a population of patients with complete implementation fidelity to CD4-stratified timing of ART 
initiation. We overcame this by using the parametric g-formula to estimate mortality in the 
cohort under the counterfactual scenario of complete implementation fidelity.[46-48]  Figure 3.3 
provides a step-by-step overview of this methodological approach.[46] 
We built a logistic regression model to assess the association between initiating ART per 
strategy and mortality (step 1), including baseline covariates hypothesized to be potential 
confounders (depicted in the directed acyclic graph in Figure 3.4). We then used parameter 
estimates from the model to calculate predicted probabilities of death for each patient based on 
their baseline covariates and observed ART timing (step 2). This modeling method imputes an 
outcome for each patient based on the average risk across patients with observed outcomes with 
the same baseline characteristics. Consequently, the outcome of participants who were LTFU is 
no longer missing, as these participants are assigned an outcome based on their baseline 
characteristics. By averaging these predicted probabilities of death across all participants, we 
estimated the risk of mortality in the full cohort under the observed, real-life level of 
implementation fidelity (step 3). 
To estimate the causal effect of implementation fidelity, a (counterfactual) probability of death 
corresponding to what would have happened to each participant had he or she initiated ART per 
strategy is needed. We calculated this probability of death based on the outcomes of patients 
with similar baseline characteristics who did initiate ART per strategy (step 4). Note that for 
patients who actually did initiate ART per strategy, this predicted probability of death is the 
same as that calculated in step 2. By averaging these probabilities, we estimated the risk of 
mortality in the full cohort under a scenario of complete (100%) implementation fidelity (step 5).  
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We then calculated the risk difference (RD) by subtracting this mortality risk estimate in the 
cohort with complete fidelity from the mortality risk estimate in the cohort with observed fidelity 
(step 6). Bootstrapping was used to generate the 95% confidence interval around the risk 
difference. This was done by creating multiple (n=500) datasets through random selection of 395 
individuals with replacement from the original ITART study population, followed by rerunning 
step 1 through step 6, and using the standard error across all the risk differences estimates (step 
7).  Finally, we estimated the preventable fraction by dividing the RD by the estimated risk in the 
cohort under observed, real-life implementation fidelity (step 7). This measure is interpreted as 
the fraction of mortality that could be prevented if 100% implementation fidelity is achieved. 
As a worked example, we apply this method for Patient X, who is 32 year old male, whose ART 
initiation was not per strategy, was tolerating TB treatment, had a CD4 of 45 cells/mm3, did not 
have any contraindication to ARVs, was diagnosed with smear-positive pulmonary TB, was 
WHO stage 3, and underweight (BMI <18.5).The logistic regression model that includes a 
variable corresponding to whether the patient initiated ART per strategy and covariates included 
in Table 1generated regression parameters such that: 
Ln[P(D=1|X=x)]=  -2.6590 + 0.0305(age) + -0.6731(female) + -0.9064(per_strategy) +                 
-2.5365(tb_tx_tolerated) + 2.0222(cd4_less_50) + 0.6315(cd4_50_99) + 0.7738(cd4_200_350)+ 
0.2346(contraindication) + 0.3727(smear_neg) + 0.0296(extrapulmonary) + 0.3744(who_4)  
+0.8832(underweight) 
Scenario 1: Observed fidelity to CD4-stratified strategy for timing of ART initiation 
As shown in the calculation below, for Patient X, the (factual) predicted probability of death 
under his observed fidelity to ART timing was 21%: 
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Ln[P(D=1|X=x)]= -2.6590 + 0.0305(32) + -0.6731(0) + -0.9064(0) + -2.5365(1) + 2.0222(1) + 
0.6315(0) + 0.7738(0)+ 0.2346(0) + 0.3727(0) + 0.0296(0) + 0.3744(0)+ 0.8832(1) 
Ln [P(D=1|X=x)]= -1.3141 
P(D=1|X=x)=[ exp(-1.3141)]/[1+ exp(-1.3141)]=0.21 
 
Scenario 2: Complete Fidelity to CD4-stratified timing of ART initiation 
In order to estimate the (counterfactual) predicted probability of for Patient X under complete 
fidelity to ART timing, we used the same regression parameters and baseline characteristics, 
however, we enter a “1” instead of a “0” for the coefficient corresponding to the regression 
parameter for ART per strategy. As shown in the calculation below, for Patient X, the predicted 
probability of death under complete fidelity was 9.5%: 
Ln[P(D=1|X=x)]= -2.6590 + 0.0305(32) + -0.6731(0) + -0.9064(1) + -2.5365(1) + 2.0222(1) + 
0.6315(0) + 0.7738(0)+ 0.2346(0) + 0.3727(0) + 0.0296(0) + 0.3744(0)+ 0.8832(1) 
Ln[P(D=1|X=x)]= -2.251 
P(D=1|X=x)=[ exp(-2.251)]/[1+ exp(-2.251)]=0.095 
From this example, it is clear that for patients whose observed ART initiation was per strategy, 
the predicted probability under complete fidelity (Scenario 2) would be the same as the predicted 
probability under observed fidelity (Scenario 1).
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 Table 3.1 Definition of Key Covariates of Interest for Analyses of CD4-Stratified ART Timing 
Covariate Assessment in ITART Study Definition Used in Analyses 
DEMOGRAPHIC   
Gender Patient self-reported gender at enrollment as 
either female or male 
Female v. male 
Age Patient self-reported age in years at 
enrollment 
Aim1: ≥40 years v. <40 years 
Aim2: age in years 
Marital Status Patient self-reported marital status as either 
married or unmarried at enrollment 
Married v. unmarried 
Education Patient self-report of highest level of 
education completed as either none, primary, 
secondary, or higher education. 
≥Secondary or <Secondary 
Employment Patient self-report of employment status as 
either employed or unemployed at enrollment. 
Employed or unemployed 
Mode of transport to clinic Patient self-report of model of transport to 
clinic as walking, taking a taxi/bus, or other to 
be specified. 
Walking v. vehicle 
Travel time to clinic Patient self-report of travel time in minutes to 
clinic. 
≥30 minutes v. <30 minutes 
TB VARIABLES   
Type of TB Data on sputum-smear status as either 
positive or negative and site of TB disease as 
either pulmonary or extrapulmonary both 
were abstracted from the TB clinical records 
at baseline. 
Smear-positive pulmonary v. smear-
negative pulmonary v. extrapulmonary 
(including both) 
History of TB Data on history of TB as either new, relapse, 
failure, or return after default were abstracted 
from the TB clinical records at baseline. 
History of TB (not new) v. no history of 
TB (new) 
Toleration of TB treatment Subjective provider assessment of the patient 
at the scheduled ART initiation visit as either 
tolerating (yes) or not tolerating TB treatment 
(no). 
Intolerance of TB treatment (no) v. 
toleration of TB treatment (all other 
patients)  
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Disclosure of TB status Patient self-report of either disclosing or not 
disclosing their TB diagnosis to other 
healthcare worker, partner, household 
member, friend, family member, employer, or 
other specified person. 
Disclosure of TB (yes to one or more 
person) v. non-disclosure of TB 
HIV VARIABLES   
Contraindication to ARV Provider report of patient contraindication to 
any of the following ARVs that were 
available in ITART: EFZ, NVP, d4T, and 
AZT. 
Contraindication to any ARV v. no 
contraindication to any ARV 
HIV diagnosis at TB clinic This variable was assessed based on whether 
the patient self-reported as HIV-positive at 
the time of TB diagnosis. These patients were 
re-tested as a part of the study to confirm their 
HIV diagnosis. 
HIV diagnosis at TB clinic (newly 
diagnosed) v. HIV diagnosis prior to TB 
clinic 
Baseline CD4 cell count Blood draw for selected laboratory testing 
(including CD4 count) was done at 
enrollment visit and specimens were sent to a 
central laboratory for processing. 
Baseline CD4 count was defined as the 
result available within 30 days of TB 
treatment start date, since this is the value 
that would have been considered in ART 
timing per strategy. 
WHO clinical stage WHO clinical staging was assessed by the 
study nurse at enrollment based on National 
Institute of Allergy and Infectious Disease, 
Division of AIDS (NIAD DAIDS) standard 
guidelines. All patients with pulmonary TB 
are WHO stage 3 by default. Patients with 
HIV wasting syndrome, pneumocystis 
pneumonia, recurrent bacterial pneumonia, 
herpes simplex, esophageal candidiasis, 
Karposi’s sarcoma, cerebral toxoplasmosis, 
HIV-associated encephalopathy, or 
extrapulmonary TB were defined as WHO 
stage 4. 
WHO stage 4 v. WHO stage 3 
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Disclosure of HIV status Patient self-report of either disclosing or not 
disclosing their HIV diagnosis to other 
healthcare worker, partner, household 
member, friend, family member, employer, or 
other specified person. 
Disclosure of HIV (yes to one or more 
person) v. non-disclosure of HIV 
GENERAL CLINICAL 
VARIABLES 
  
Hospitalization in the prior year Patient self-report at enrollment of whether or 
not they have ever been hospitalized. For 
patients who reported prior hospitalization, 
the year of hospitalization was also noted.  
Hospitalization in the calendar year prior 
to the calendar year of TB treatment start 
v. not (all other patients) 
Functional status Health provider assessment of the patient’s 
functional status at enrollment as: no 
limitations, ambulatory, in bed more than 
usual, bedridden).   
Poor (in bed more than usual or 
bedridden) v. good (no limitations or 
ambulatory) 
Body mass index (BMI) Height and weight were assessed and 
recorded by the provider at enrollment. BMI 
is calculated as weight in kilograms divided 
by height in meters squared. 
Standard BMI categories of: underweight 
<18.5, normal 18.5-25, overweight 25-30 
overweight, >30 obese. 
Alcohol use Patient self-report on two alcohol-related 
variables that ask about frequency of drinking 
during a given week and the quantity of 
alcohol consumed in one sitting. There were 
few patients who met the definition of heavy 
drinking (frequent and high quantity). 
Any alcohol use v. no alcohol use. 
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Figure 3.1 Application of Inclusion/Exclusion Criteria to Generate Analytical Populations
• Diagnosed with TB at ITART 
clinic  
• Confirmed HIV infection  
• ART-naïve or ART-experienced 
and willing to continue ART at 
ITART clinic  
• Provided informed Consent 
Enrolled in ITART Study 
N=599 
 
Age ≥13 years at enrollment 
N=581 
Baseline CD4 available 
N=492 
ART-naïve at enrollment 
N=524 
 
Enrolled in ITART within 1 month of TB treatment 
N=559 
Included in Analytical Population Aim1 
N=492 
Scheduled to initiate ART at 1 or 2 months 
N=395 
Included in Analytical Population for Aim2 
N=395 
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Figure 3.2 Graphical depiction of analytical approach to examine the effect implementation 
fidelity to CD4-stratified timing of ART initiation on mortality
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Figure 3.3 Steps of the parametric g-formula method to estimate the risk difference between the 
ITART population under observed and complete implementation fidelity to  
timing of ART initiation per CD4-stratified strategy 
 
1. Build a logistic regression model of the association between initiating ART per strategy 
and mortality. 
 
2. Use parameter estimates from model to calculate predicted probabilities of death for each 
patient based on their baseline factors (summarized in Table1) and observed ART timing. 
 
3. Estimate the risk of death in the ITART population with observed fidelity to ART timing 
per CD4-stratified strategy, by taking the average of the predicted probabilities across all 
patients. 
 
4. Recalculate predicted probabilities for each patient under scenario of complete fidelity to 
ART timing per CD4-stratified strategy. 
 
5. Estimate the risk of death in the ITART population with complete fidelity to ART timing 
per CD4-stratified strategy by taking the average of the predicted probabilities of death 
calculated in step4 across all patients. 
 
6. Estimate the risk difference by subtracting the risk of death in the ITART population with 
complete fidelity from the risk of death in the ITART population with observed fidelity.  
 
7. Bootstrap the 95% confidence interval around the risk difference by creating multiple 
datasets through random selection with replacement from the original ITART population, 
rerunning steps 1-6, and using the standard error across all the risk differences estimates. 
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Figure 3.4 Direct Acyclic Graph (DAG) of Association between ART Initiation Per CD4-
Stratified Timing and Mortality 
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CHAPTER FOUR: TIMING AND PREDICTORS OF DELAY OF ANTIRETROVIRAL 
THERAPY INITIATION AMONG PATIENTS RECEIVING INTEGRATED 
TUBERCULOSIS AND HIV TREATMENT 
 
Characteristics at Baseline and Scheduled ART Initiation 
Between August 2007 and November 2009, 599 patients diagnosed with TB and HIV were 
enrolled within the ITART study. Among them, 107 were sequentially excluded based on 
age<13 years (n=18), enrollment more than one month after TB treatment initiation (n=22), 
exposure to ART prior to enrollment (n=35), and lack of baseline CD4 count (n=32). The 
remaining 492 patients were included in the analysis.  
Baseline characteristics of these patients are shown in Table 4.1. Participants were 60.0% 
female, 44.5% married, and had a median age of 38 years (IQR 32-45). Most (92.3%) patients 
were of low SES, less than half (46.3%) were employed, and 61.6% had at least completed 
secondary education. The majority (75.4%) of patients walked to the clinic, with about half 
(48.6%) spending over 30 minutes to get to the clinic. Of patients with pulmonary TB (79.7%), 
half were smear-negative. Overall 25.4% had a prior history of TB treatment. Most (95.3%) 
patients were newly diagnosed with HIV as part of the TB diagnostic process.  
At baseline, median CD4 count was 168 cells/mm3 (IQR 84-307) and 22.4% of patients were 
WHO clinical stage 4. Only 15.7% of patients had been hospitalized in the prior year, and few 
(5.5%) of patients had poor functional status. The median BMI was 17.9 (IQR 16.5-19.9) and 
over half (57.5%) of patients were underweight. At baseline, nearly all (89.2%) patients had 
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disclosed their TB status, while less than half (40.0%) had disclosed their HIV status. At their 
scheduled ART initiation visit, 145 (29.5%) of patients were assessed by the health provider as 
not tolerating TB treatment. In total, 26 (5.3%) of patients had contraindication to one or more 
antiretroviral drug. Reasons for contraindication included: pre-existing peripheral neuropathy for 
stavudine (n=22), pregnancy for efavirenz (n=1), and anemia for zidovudine (n=2).  
Timing of ART Initiation 
A total of 143 (29.1%) patients were eligible for ART initiation at 1 month of TB treatment, 
nearly all (n=141) because of CD4<100 cells/mm3. Another 252 (51.2 %) patients were eligible 
for ART initiation at 2 months of TB treatment, based on CD4 100-350 cells/mm3. The majority 
(58.8%, n=57) of patients with baseline CD4 >350 (n=97) were eligible for ART initiation at 
completion of TB treatment based on a CD4 ≤350 cells/mm3 at month 5 (n=18), lack of follow-
up CD4 count (n=32), or incident WHO stage 4 condition (n=7).  
Overall, ART initiation was delayed in 235 (47.8%) patients (details in Figure 4.1). Patients 
scheduled to initiate ART at 2 months were less likely to experience delay in ART compared to 
patients scheduled to initiate ART at 1 month (45.2% v. 58.7%, p=0.010) and compared to 
patients scheduled to initiate ART at TB treatment completion (45.2% v. 64.9%, p=0.007). 
Among the 235 (47.8%) who experienced delay in ART, 171 (72.8%) initiated ART late, after a 
median of 12 days (IQR 4-27) beyond the time of eligibility plus 5 days and 64 (27.2%) never 
initiated ART. ART initiation was delayed by the provider in five patients for a median of 13 
days (IQR 13-19) due to untreated oral candidiasis (n=4) and short-term travel outside of 
Kinshasa (n=1). 
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Of the 86 patients who never initiated ART, eight died a median of 20 days (IQR 8-30) before 
the time of eligibility for ART initiation. Of these, two had baseline CD4 count <100 cells/mm3, 
five had baseline CD4 count 100-350 cells/mm3, and one had baseline CD4 count >350 
cells/mm3. Fourteen patients were lost-to-follow-up prior to the date they became eligible for 
ART initiation. One patient was considered ineligible for ART due to the presence of a terminal 
illness at their scheduled ART initiation visit and died thereafter. Three patients refused ART as 
they did not feel ready to start long-term therapy. Two patients who never initiated ART self-
reported suboptimal adherence to TB treatment (at least one missed dose within the prior four 
days) at the scheduled time of ART initiation. 
Predictors of Delay in ART Initiation 
Crude and fully adjusted model results are shown in Table 4.2. After backwards elimination, the 
final model indicated that lower CD4 count, lack of disclosure of HIV status, contraindication to 
one or more ARV drugs, and intolerance of TB drugs were predictive of delay of ART initiation. 
Patients with contraindication to at least one antiretroviral drug were more likely to experience 
delayed ART initiation (adjOR 2.91, 95% CI 1.22-6.95). Lower CD4 count at baseline was 
associated with 20% higher odds of delayed ART initiation (adjOR 1.20, 95% CI 1.08-1.33 per 
100 CD4 cell/mm3). Patients who did not tolerate their TB drugs were nearly 2 times as likely to 
experience delay in ART initiation (adjOR 1.93, 95% CI 1.23-3.02). Failure to disclose HIV 
status, was associated with delayed ART initiation (adjOR 1.50, 95% CI 1.03-2.18). These 
predictors were robust to sensitivity analysis in which the definition of delayed ART initiation 
was expanded to include patients who were LTFU prior to the time eligibility. The full model 
results suggest that not being married (adjOR 1.46, 95% CI 0.99-2.16) and smear-negative 
pulmonary TB (v. smear-positive pulmonary TB) (adjOR 1.52, 95% CI 0.98-2.34) may be 
 43 
 
predictive of delayed ART initiation, although they did not meet the a priori criteria for retention 
in the final model. 
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Table 4.1 Characteristics at baseline of 492 patients participating in the Integrated Tuberculosis 
and Anti-Retroviral Treatment (ITART) study at five primary  
care clinics in Kinshasa, Democratic Republic of Congo 
Characteristic n % 
Female 295 60.0 
Age   <30 94 19.1 
30-39 182 37.0 
40-49 184 33.3 
≥50 52 10.6 
Married 219 44.5 
Completed secondary education 303 61.6 
Employed 228 46.3 
Low socio-economic status 454 92.3 
Walk to clinic 371 75.4 
Travel time to clinic (minutes)      <10 18 3.7 
                                             10-19 141 28.7 
                                             20-29 94 19.1 
                                             30-39 136 27.6 
                                              ≥40 103 20.9 
TB type    Smear + Pulmonary 193 39.2 
  Smear – Pulmonary 199 40.5 
  Extrapulmonary 100 20.3 
History of TB 125 25.4 
HIV diagnosis at TB clinic 469 95.3 
CD4 count (cells/mm3)       <50 77 15.6 
                                  50-99 64 13.0 
                                  100-199 136 27.6 
                                  200-350 118 24.0 
                                   >350 97 19.7 
Hospitalization in Prior Year 77 15.7 
Poor Functional Status 27 5.5 
BMI      Underweight (<18.5) 283 57.5 
   Normal (18.5-24.9) 194 39.4 
   Overweight (25.0-29.9) 12 2.4 
   Obese (≥30) 3 0.6 
Alcohol use (any) 201 40.9 
Disclosure of TB status 439 89.2 
Disclosure of HIV status 197 40.0 
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Figure 4.1 Distribution of ART eligibility, expected timing of ART initiation, and observed 
timing of ART initiation in 492 patients receiving integrated TB and HIV 
 treatment at five primary care clinics in Kinshasa, Democratic Republicof Congo.* 
 
TB=tuberculosis; ART=antiretroviral therapy; CD4=CD4 count in cells/mm3; shading=delayed 
ART; median (IQR)=median and interquartile range of time to ART initiation from TB treatment 
start. *Expected timing of ART is at 1 month or 2 months from the start of TB treatment or at 
completion of TB treatment with a +5 day window around these timepoints to accommodate 
scheduling limitations, clinic closure on weekends and holidays, and on-site availability of 
consulting physician.
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Table 4.2 Predictors of Delayed ART Initiation in 492 patients participating in the Integrating Tuberculosis and Anti-Retroviral 
Treatment (ITART) study at five primary care clinics in Kinshasa, Democratic Republic of Congo 
 
Crude OR 
Univariate Model 
(95% CI) 
Adjusted OR 
Full Model 
(95% CI) 
Adjusted OR 
Reduced Model 
(95% CI) 
Female 1.00 (0.70-1.44) 0.97 (0.65-1.45) -- 
Age >40 years 1.06 (0.74-1.52) 1.01 (0.68-1.51) -- 
Married 0.73 (0.51-1.04) 0.69 (0.46-1.01) -- 
Secondary Education 0.88 (0.61-1.27) 0.94 (0.64-1.40) -- 
Employed 0.88 (0.62-1.26) 1.04 (0.69-1.58) -- 
Low SES 0.57 (0.29-1.12) 0.59 (0.29-1.22) -- 
Walk to Clinic 0.80 (0.53-1.20) 0.83 (0.54-1.16) -- 
Travel Time >30 min 0.85 (0.59-1.20) 0.79 (0.54-1.16) -- 
TB Type   Smear + Pulmonary referent referent referent 
  Smear – Pulmonary 1.42 (0.95-2.12) 1.52 (0.98-2.34) -- 
  Extrapulmonary 1.15 (0.71-1.87) 1.03 (0.61-1.72) -- 
History of TB 0.85 (0.57-1.28) 0.87 (0.56-1.35) -- 
HIV diagnosis at TB clinic 1.20 (0.52-2.79) 0.89 (0.36-2.20) -- 
CD4 count (per 100 cells/mm3 decrease) 1.12 (1.02-1.23) 1.18 (1.06-1.32) 1.20 (1.08-1.33) 
Prior Hospitalization 1.01 (0.62-1.65) 0.92 (0.54-1.54) -- 
Poor Functional Status 1.19 (0.55-2.59) 1.42 (0.60-3.33) -- 
Underweight (BMI<18.5) 0.90 (0.63-1.29) 0.89 (0.60-1.33) -- 
Alcohol use (any) 0.97 (0.67-1.39) 0.96 (0.65-1.43) -- 
Non-disclosure of TB status 1.15 (0.65-2.04) 0.87 (0.46-1.64) -- 
Non-disclosure HIV status 1.46 (1.02-2.10) 1.60 (1.05-2.44) 1.50 (1.03-2.18) 
Contraindication to ART* 2.58 (1.10-6.05) 2.90 (1.17-7.20) 2.91 (1.22-6.95) 
Intolerance of TB Drugs* 1.36 (0.92-2.00) 1.93 (1.21-3.07) 1.93 (1.23-3.02) 
OR=odds ratio; CI=confidence interval, SES=socio-economic status. *determined at scheduled ART initiation date (see text for 
details)
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CHAPTER 5: CHAPTER FIVE: EFFECT OF CD4-STRATIFIED TIMING OF 
ANTIRETROVIRAL THERAPY INITIATION ON MORTALITY IN PATIENTS 
DIAGNOSED WITH TUBERCULOSIS IN A HIGHLY RESOURCE-LIMITED SETTING 
 
Baseline Characteristics of Analytical Cohort 
Between August 2007 and December 2009, 599 participants enrolled in the ITART study. 
Among them, 204 were sequentially excluded based on age<13 years (n=18), lack of baseline 
CD4 count (n=88), enrollment more than one month after TB treatment initiation (n=1), 
exposure to ART prior to enrollment (n=0), and CD4>350 (n=97). The remaining 395 
participants were included in the analysis. 
Baseline characteristics of patients are presented in Table 5.1. Most (80%) participants were 
diagnosed with pulmonary TB. Type of TB was smear-positive pulmonary in 35%, smear-
negative pulmonary in 45%, and extrapulmonary in 20% of patients. Just over half (59%) were 
female and median age was 38 (IQR: 32-45). Most patients were underweight (median BMI 
17.8, IQR: 16.5-19.7; 59.2% BMI<18.5). Patients presented late in the HIV disease process, with 
a median CD4 count of 131 cells/mm3 (IQR: 63-224). Of the 143 (36%) patients eligible for 
ART at 1 month, 77 (54%) had CD4<50 cells/mm3, 64 (45%) had CD4 50-99, and 2 (1%) had 
CD4>100 and WHO stage 4. Of the 252 (64%) patients eligible for ART at 2 months, 136 (54%) 
had CD4 100-199 and 116 (46%) had CD4 200-350. Few (n=24, 6%) of patients had 
contraindication to one or more antiretroviral drugs.                                                                                                                
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Implementation Fidelity to CD4-stratified Timing of ART Initiation  
Overall, 183 (46%) participants initiated ART per strategy. Among the 212 (54%) participants 
who initiated ART not per strategy, 53 (25%) never initiated ART and 159 (75%) initiated ART 
with a median delay of 11 days (IQR: 4-24). Median delay did not differ by time of eligibility 
(12 days for 1 month v. 10 days for 2 months, p=0.62). Patients whose timing of ART initiation 
was per strategy had higher CD4 count (151 v. 113 cells/mm3, p=0.002) and higher frequency of 
tolerating their TB drugs (96% v. 70%, p<0.0001) at the scheduled time of ART initiation than 
patients whose timing of ART initiation was not per strategy. 
Predictors of Mortality in First Six Months of TB Treatment 
Results of predictive modeling of mortality are presented in Table 5.2. In a series of crude 
(unadjusted) models, CD4 count <50 cells/mm3 (OR 6.0, 95% CI: 2.2-16.4), and TB treatment 
intolerance (OR 12.3, 95% CI: 5.6-27.3) were predictive of mortality. In the final (reduced) 
model, TB treatment intolerance (adjOR 12.7, 95% CI: 4.8-33.2), CD4 count <50 cells/mm3 
(adjOR 7.3, 95% CI: 2.3-23.3), and male gender (adjOR 2.4, 95% CI: 1.0-5.6) were predictive of 
mortality. In addition, underweight (adjOR 2.2, 95% CI: 0.9-5.6), and not initiating ART per 
strategy (adjOR 2.5, 95% CI: 0.9-6.6) doubled the risk of mortality, although not statistically 
significantly. 
Mortality under Observed Implementation Fidelity to CD4-stratified ART initiation 
During the first six months of TB treatment, 33 participants died and 47 (11.9%) were LTFU.  
Among the 348 (88.1%) patients with an observed outcome, the six-month mortality risk was 
9.5% (6.4-12.6%). The majority (n=26) of these deaths occurred in participants whose timing of 
ART initiation deviated from the CD4-stratified strategy.  
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When estimating the risk in the full cohort (i.e. including those LTFU) using the predicted 
outcome probabilities from the logistic regression model, the six-month mortality risk under 
observed implementation fidelity was 12.0% (95% CI: 8.2-15.7%). 
Causal effect of implementation fidelity on six-month mortality 
As shown in Table 4.3, complete fidelity to the CD4-stratified timing strategy for ART initiation 
in this population was estimated to result in a six-month mortality risk of 7.8% (95% CI: 2.4-
12.3%), corresponding to a -4.2% risk difference (95% CI: -8.1, -0.3%). The preventable fraction 
of mortality due non-fidelity to the CD4-stratified ART initiation strategy was 35.1% (95% CI: 
2.9-67.9%), suggesting that just over one third of observed mortality is preventable by fidelity to 
CD4-stratified ART initiation. These mortality estimates were robust to sensitivity analyses in 
which the definition of ART initiation per strategy was narrowed to exclude patients who were 
LTFU prior to the time eligibility (RD -4.1%, 95% CI: -7.8, -0.5% and preventable fraction 
34.6%, 95% CI: 3.8-65.3%). 
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Table 5.1 Baseline characteristics of patients in the Integrating Tuberculosis and Anti-Retroviral Treatment (ITART) study analytical 
population by timing of ART initiation per CD4-stratified strategy (N=395) 
Baseline Characteristic All Patients Timing of ART 
initiation per  
CD4-stratified strategy 
Timing of ART 
initiation deviating 
from CD4-stratified 
strategy 
p-value 
 n %* n %* n %*  
Total 395 100 183 46.3 212 53.7 -- 
Female 231 58.5 103 56.3 128 60.4 0.41 
Age (years), median (IQR) 38 32-45 38 32-45 38 32-45 0.97 
<30 65 16.5 32 17.5 33 15.6 0.61 
30-39 158 40.0 73 39.9 85 40.1 0.97 
40-49 129 32.7 56 30.6 73 34.4 0.42 
≥50 43 10.9 22 12.0 21 9.9 0.50 
TB type    Smear + Pulmonary 139 35.2 71 38.8 68 32.1 0.16 
  Smear – Pulmonary 176 44.6 77 42.1 99 46.7 0.36 
  Extrapulmonary 80 20.3 35 19.1 45 21.2 0.60 
CD4 count (cells/mm3), median (IQR) 131 63-224 151 77-243 113 60-190 0.002 
<50 77  19.5 33 18.0 44 20.8 0.50 
                                 50-99 64 16.2 21 11.5 43 20.3 0.02 
                                  100-199 136 34.4 61 33.3 75 35.4 0.67 
                                  200-350 118 29.9 68 37.2 50 23.6 0.003 
BMI, median (IQR) 17.8 16.5-19.7 17.7 16.4-19.6 17.8 16.6-19.8 0.35 
Underweight (<18.5) 234 59.2 114 62.3 120 56.6 0.25 
   Normal (18.5-24.9) 148 37.5 64 35.0 84 39.6 0.34 
   Overweight (25.0-29.9) 11 2.8 4 2.2 7 3.3 0.56 
   Obese (≥30) 2 0.5 1 0.6 1 0.5 1.0 
Toleration of TB drugs 322 81.5 175 95.6 147 69.3 <0.0001 
Contraindication to any ARV drug 24 6.1 7 3.8 17 8.0 0.09 
WHO stage 90 22.8 41 22.4 49 23.1 0.87 
*percentage reported unless noted otherwise; IQR=interquartile range; ART=antiretroviral therapy; ARV=antiretroviral
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Table 5.2 Predictors of mortality in 395 HIV-infected patients diagnosed with TB with observed implementation fidelity to CD4-
Stratified timing of ART initiation 
 Crude OR 
Univariate Model 
(95% CI) 
Adjusted OR 
Full Model 
(95% CI) 
Adjusted OR 
Reduced Model 
(95% CI) 
Gender                                                     Male 1.78 (0.86-3.65) 1.97 (0.76-5.09) 2.37 (1.00-5.61) 
                                                                 Female 1 1 1 
Age (years)                                               <30 1.36 (0.44-4.17) 1.26 (0.32-4.96) - 
                 30-39 1 1 - 
                 40-49 1.72 (0.71-4.14) 1.86 (0.64-5.37) - 
                    ≥50 2.40 (0.82-7.07) 2.96 (0.77-11.4) - 
Type of TB                                                Smear + Pulmonary 1 1 - 
                  Smear – Pulmonary 2.01 (0.81-4.98) 1.43 (0.48-4.24) - 
                  Extrapulmonary 2.05 (0.71-5.91) 1.11 (0.07-17.79) - 
CD4 count (cells/mm3)                            <50 5.99 (2.19-16.36) 7.66 (2.27-25.8) 7.30 (2.29-23.3) 
                  50-99 1.81 (0.53-6.19) 1.92 (0.47-7.86) 1.94 (0.49-7.59) 
                  100-199 1 1 1 
                  200-350 1.36 (0.44-4.17) 2.19 (0.58-8.20) 1.95 (0.56-6.79) 
BMI category                                             Underweight (<18.5) 1.92 (0.87-4.27) 2.46 (0.94-6.2) 2.21 (0.89-5.62) 
                                                                   Not Underweight (≥18.5) 1 1 1 
TB treatment intolerance                           Yes 12.33 (5.56-27.31) 12.75 (4.69-34.71) 12.65 (4.82-33.20) 
                                                                   No 1 1 - 
Contraindication to any ARV                   Yes 0.90 (0.20-4.04) 1.43 (0.48-4.24) - 
                                                                   No 1 1 - 
WHO stage                                                 4 1.34 (0.59-3.01) 1.28 (0.10-16.1) - 
                                                                    3 1 1 - 
ART initiation                                             Not per strategy 4.25 (1.79-10.07) 2.52 (0.93-6.86) 2.47 (0.93-6.55) 
                                                                    Per strategy 1 1 1 
OR=odds ratio; TB=tuberculosis; BMI=body mass index; ARV=antiretroviral; WHO=World Health Organization; ART=antiretroviral 
therapy
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Table 5.3. Six-month mortality risk in the Integrating Tuberculosis and Anti-Retroviral Treatment 
(ITART) study population (N=395)under observed and complete  
implementation fidelity to timing of ART initiation per CD4-stratified strategy 
 Estimate (95% CI) 
Observed Risk in ITART population * 0.095 (0.064-0.126) 
Estimated Risk in ITART population with observed implementation fidelity 
of the CD4-stratified ART initiation strategy 
0.120 (0.082,0.157) 
Estimated Risk in ITART population with complete fidelity to the CD4-
stratified ART initiation strategy 
0.078 (0.024, 0.123) 
Estimated Risk Difference in mortality between observed and complete 
implementation fidelity 
-0.042 (-0.081, -0.003) 
Estimated Preventable fraction of mortality under complete implementation 
fidelity 
0.351 (0.029, 0.679) 
*excludes 47 patients missing six-month mortality outcome. 
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CHAPTER SIX: DISCUSSION 
Despite full integration of TB treatment and ART by the same provider at the same primary 
health care TB clinic space, delay in ART initiation was common, with only half of all HIV-
infected TB patients initiated ART per CD4-stratified timing strategy. This finding of low 
implementation fidelity suggests that the 2012 WHO recommendation that calls for CD4-
stratified timing of ART initiation [49], may be challenging to implement in resource-limited 
routine clinical care. 
Our finding of delay in ART initiation despite full integration of TB and HIV treatment confirms 
the finding of two studies in South Africa. In a before-after study, Kershberger et al. found that 
integration reduced median time to ART initiation from 147 to 75 days after TB treatment start. 
Half of all patients still initiated ART after 75 days; a timeframe that is late given a median CD4 
cell count 84 cells/mm3 (IQR 32-158) in the study population.[40]  In the Starting Antiretroviral 
Therapy at Three Points in Tuberculosis (SAPiT) study, a randomized controlled trial of ART 
timing in patients diagnosed with TB, 16.7% of patients assigned to early ART (within 4 weeks 
of TB treatment start) and 28.7% of patients assigned to late ART (within 4 weeks of the 
continuation phase) did not initiate ART per study protocol. [33] 
Our study is the first to evaluate patient-level factors predictive of delayed ART initiation in an 
integrated TB/HIV treatment setting. Delayed ART initiation was more likely among those with 
lower CD4 count, no HIV disclosure, intolerance of TB drugs, and contradiction to an ARV 
drug. Two prior studies of delay in ART initiation among patients diagnosed with TB were 
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performed in a non-integrated setting. [21, 22] Similar to our findings, these studies found that 
smear-negative pulmonary TB was associated with delay in ART initiation, which may be 
related to the additional complexity and time required for a final diagnosis of this form of TB.[50] 
In contrast to our findings, these studies found that lower CD4 count was associated with less 
delay. This contradictory finding may be due to the fact that the outcome in these studies was 
absolute time to ART, without consideration of baseline CD4 count or clinical stage and that 
these studies only included patients who reached the ART clinic and initiated ART. The outcome 
in our study was delayed ART initiation, defined based on the study protocol, which 
recommended earlier ART initiation for patients with lower CD4 count. Consequently, our 
finding of lower CD4 count as a predictor, may in fact, reflect the challenge of early ART 
initiation due to a number of factors including patient readiness to immediately start life-long 
ART, potential for immune reconstitution inflammatory syndrome[33, 34][51], non-adherence due to 
increased pill burden, and overlapping drug toxicities.[52] Additionally, we found that intolerance 
of TB treatment was predictive of delayed ART initiation, suggesting that both providers and 
patients may be reluctant to initiate ART until TB treatment is tolerated. Our finding that non-
disclosure of HIV status was predictive of delayed ART initiation is consistent with other studies 
that have found an association between non-disclosure of HIV status and lack of readiness to 
initiate ART, which may be related to social support and fear of stigma; factors that may also 
explain why being non-married was a potential predictor in our study [53-55].   
Our finding of patient-level factors associated with delayed ART can inform additional policy 
and programmatic interventions. Patient-level factors can influence both patient and health 
provider perceptions and decision-making about ART initiation; therefore, interventions should 
be designed accordingly. Training of health providers and health communication messaging to 
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patients should emphasize the importance of early ART initiation, particularly among patients 
presenting with low CD4 count. Availability of more than one first-line antiretroviral regimen 
could help expedite ART initiation in patients with one or more drug contraindications. 
Furthermore, since severity of TB drug intolerability may vary substantially, clear guidance to 
health providers on the severity of TB drug intolerance that warrants delay of ART is needed. 
Finally, provider-initiated testing and counseling for HIV should emphasize and facilitate safe 
HIV disclosure by patients; an essential component of the HIV prevention package that was 
associated with timely ART initiation in our study. 
Under the condition of low implementation fidelity to the CD4-stratified ART initiation strategy, 
the six-month mortality estimate risk in the full cohort was 12.0%. This estimated risk was 
higher than the observed risk (9.5%) because patients who were LTFU and missing an outcome, 
had a higher risk of mortality based on their baseline characteristics. Although not unexpected 
given that many of the risk factors for LTFU are also risk factors for mortality; this finding 
suggests that risk of mortality would have underestimated in a complete-case analysis. This 
finding also suggests that even if these patients had been retained in care, a relatively large 
proportion may have died. Under the scenario of 100% fidelity to the CD4 count stratified ART 
initiation strategy, we found a 4.2% (95% CI 0.03% to 8.1%)  reduction in the six-month 
mortality risk, representing a 35.1% preventable fraction of mortality in this population. There 
were ten patients whose predicted probability of death was greater than 50% even under the 
scenario of complete fidelity to timing of ART initiation per CD4-stratified timing. All ten had 
baseline CD4 count <50 cells/mm3 and did not tolerate TB treatment, suggesting that additional 
interventions beyond timely ART initiation may be necessary to prevent death in these patients. 
Since the definition of TB treatment intolerance is inherently non-specific, patients with severe 
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immunosuppression who are assessed as not tolerating TB treatment may in fact have other 
underlying clinical conditions that may contribute to mortality and require attention beyond that 
available at the primary care level. 
Few studies have quantified implementation fidelity to international guidelines for resource 
limited settings, including those for integrated TB/HIV care and treatment and we are not aware 
of any studies that have attempted to estimate the gain that can be achieve by reaching 100% 
implementation fidelity. This is an important limitation as it is only by evaluating the fidelity 
with which an intervention has been implemented that a viable assessment can be made of its 
contribution to desired outcomes.[43] As such, it remains unclear based on current monitoring of 
most international public health programs whether any positive outcomes following 
implementation of new guidelines might be improved further if greater attention was paid to 
implementation fidelity. It has therefore been suggested that research of these interventions and 
their outcomes should involve an evaluation of implementation fidelity if the true effect of the 
intervention is to be discerned.[43]  
Our study provides one of the first examples of using modern epidemiological methods to 
measuring the impact of implementation fidelity to international guidelines in resource limited 
settings on desired outcomes. The parametric g-formula generates unbiased effects of the causal 
effect of an intervention using observational data when assumptions of exchangeability (no 
uncontrolled confounding or uncontrolled selection bias), positivity (patients in each treatment 
group across all strata of each covariate), and consistency (for a given treatment, the 
counterfactual outcome is equivalent to the observed outcome for each patient) are met. This 
allows investigators to extend the analysis of observational study to estimate the population 
attributable fraction that contrasts scenarios of intervention fidelity beyond the traditional all 
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versus none. We used this approach to study the risk difference between different levels of 
implementation fidelity to one intervention; however, this approach could also useful to compare 
effects across multiple or complex interventions.[46, 48, 56] We believe that the application of the 
parametric g-formula has great potential to contribute to the field of implementation science.[56, 57]  
Our study has several limitations that must be considered in the interpretation of our findings. 
First, transport for CD4 count specimens/results was provided as a part of the study to help 
ensure CD4 count was available for decision-making on timing of ART initiation. Our findings 
may not be generalizable to settings in which availability of CD4 count is limited. Second, our 
study provided additional training and support of nurses to provide integrated ART and TB 
treatment and more frequent and extensive clinical visits beyond those available in routine care. 
Consequently, our findings may not be fully generalizable to routine care provided in primary 
care clinics by nurses who do not receive this level of support. While these differences may 
impact the timing of ART in patients diagnosed with TB, we do not believe that they are likely to 
substantially influence patient characteristics associated with delayed ART initiation. Monitoring 
of ART timing and patient factors associated with delayed ART in routine settings will thus be 
important. Third, the nurses making decisions on when to initiate ART were trained and closely 
monitored as part of the research study. The degree of implementation fidelity in routine settings 
may be even lower and the causal effect of implementation fidelity may have been 
underestimated. Fourth, similar to most studies of implementation fidelity, our assessment 
focused exclusively on the adherence component by assessing whether ART was initiated on 
time. We did not evaluate other components of implementation fidelity, such as intervention 
complexity, facilitation strategies, quality of delivery and patient responsiveness, factors that can 
influence or moderate the level of adherence by health care workers to guideline 
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implementation.[43] Fifth, we focused on reduction in short-term mortality, which is only one of 
the desired outcomes of TB/HIV care. Other potentially relevant outcomes could be reduction in 
long-term mortality and treatment success for HIV (adherence to ARV medications and virologic 
suppression) and TB (adherence to TB medications and confirmed cure). 
Despite fully integrated TB/HIV treatment, nearly half of all HIV-infected patients diagnosed 
with TB experienced delay in ART initiation during TB treatment, such that timing of ART 
initiation was not per CD4-strategy. Strategies to achieve high implementation fidelity to CD4-
stratified timing of ART initiation for patients with TB at primary care clinics in resource limited 
settings need to be developed as greater implementation fidelity has the potential to reduce 
mortality. Several patient-level factors that predicted delayed ART initiation can inform the 
development and implementation of such strategies to specifically target patients identified as at-
risk of delayed ART initiation. 
There are several next steps for research on timing of ART in patients with TB based on our 
study findings and limitations. First, research is needed to compare outcomes between CD4-
stratified ART timing and early ART timing regardless of CD4. As discussed, the three major 
RCT studies assigned patients to either early or late ART timing regardless of CD4 count. In 
contrast, all patients in our study were assigned to CD4-stratified ART timing. To date, there has 
not been a comparison between CD4-stratified ART timing and early timing regardless of CD4 
count. This would be a helpful comparison to inform further development of WHO guidelines. A 
pooled analysis of ITART and one or more of the RCT studies that used a model-based 
standardization approach would allow for a comparison of ITART under the scenario of 
complete fidelity to CD4-stratified ART timing and ITART under the scenario of early ART 
timing regardless of CD4. Second, as countries implement 2012 WHO guidelines for CD4-
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stratified ART timing, research on additional outcomes of TB/HIV treatment such as long-term 
mortality, TB treatment adherence, TB cure, ART adherence, HIV viral load suppression, etc. 
are necessary. This type of research could be done in a pre/post intervention design, particularly 
if implementation of the new WHO guidelines is implemented across regions or sites gradually 
over time. Third, given our finding that several patient-level characteristics predicted delayed 
ART in an integrated TB/HIV setting, additional research that studies the impact of interventions 
that target these factors would be helpful to inform wide-scale implementation. 
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